Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Narcotic Pain (Apr 2017)

Posted by Matt Breese on Apr 10, 2017

Find me on:

According to our recent payer coverage analysis for narcotic pain treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A market access snapshot for narcotic pain treatments shows an increase in the percentage of average restricted lives. Health exchange formularies saw the greatest increase in restrictions. PAs and step edits are still prevalent.


Source: MMIT data as of Q2 2017

Trends:  Recent news related to narcotic pain treatment represent the increasing complexity of prescribing for this disease area. CDC guidelines from last year continue to drive shifts in the way prescribers prescribe and the way in which patients adhere to treatment plans. Development for this disease area is led by innovative, abuse-deterrent products.

In the full Reality Check on narcotic pain treatments below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.

To read the full Reality Check on narcotic pain treatments with key findings on clinical characteristics, narcotic pain drug market access and payer coverage, please click on the button below: 


View Reality Check


Topics: Specialty, Market Access, Branding & Marketing